One reason neglected diseases like mycetoma are so neglected: The lack of market incentives for pharmaceutical companies to develop new drugs.
Editor’s Note: This week we will highlight 5 takes on how we can reduce drug prices while preserving robust research and development, from the fall issue of Hopkins Bloomberg Public Health Magazine. Read the complete set here.
Editor’s Note: This week we will highlight 5 takes on how can we reduce drug prices while preserving robust research and development, from the fall issue of Hopkins Bloomberg Public Health Magazine. Read the complete set here.
Chemical byproducts from pharmaceuticals flow into the ocean, largely unregulated and unchecked by wastewater treatment plants.
10.5% of medical products in low- and middle-income countries are counterfeit, according to new WHO research that just scratches the surface of the problem. Since 2013, the WHO has collected 1,500 reports of fraudulent products with 42% coming from sub-Saharan Africa.…
India should overturn its August decision to grant Pfizer a patent on its pneumonia vaccine Prevnar13 (PCV13), Médecins Sans Frontières is arguing in a Delhi court today.
The US FDA approved a sensor-embedded digital pill, capable of reporting back to doctors when patients take their medicine. Patients who don't comply with their prescriptions end up getting sicker and costing the system an estimated $100 billion annually, a problem the…
Marian Wentworth’s journey to leading Management Sciences for Health, the global health NGO that works in 36 countries, didn’t have a typical beginning.
The White House has called the opioid crisis a public health emergency, stopping short of declaring a national emergency.
“Has a world with fentanyl produced a new understanding of ‘imminent risk’?” ask researchers Michael Stein and Paul Christopher, calling into question the judiciary practice of non-criminal “civil commitment”—court-ordered short-term, in-patient hospitalization—in dealing…